2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…2019 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection
*Purpose: Chronic active antibody mediated rejection (cABMR) is a major cause of long-term kidney transplant (KT) loss. Current therapies have unclear efficacy and significant side…2019 American Transplant Congress
Outcomes in Kidney Transplant Recipients after Conversion from Tacrolimus to Belatacept-Based Regimens
Columbia University Irving Medical Center, New York, NY
*Purpose: Immunosuppressive strategies for belatacept are variable and associated outcomes have not been well described. We examined outcomes among kidney transplant (KT) recipients converted from…2019 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
1Surgery, Duke University, Durham, NC, 2University of Massachusetts, Worcester, MA
*Purpose: Porcine islet xenotransplantation has progressed significantly in non-human primate (NHP) studies. However, all successful NHP studies have relied upon immunosuppressive regimens that utilize drugs…2019 American Transplant Congress
The Negative Costimulatory Pd-1/pd-l1 Pathway Is Upregulated In Early Cell-mediated Rejection
Cleveland Clinic Main Campus, Lerner Research Institute, Cleveland, OH
*Purpose: Extensive transcript analysis has been performed on grafts at the time of rejection, but gene expression preceding overt rejection is less well studied.*Methods: We…2019 American Transplant Congress
Toll Like Receptor 2 Mobilizes Regulatory T Cell Lymphatic Migration by Stimulating Lymphotoxin Expression
*Purpose: Regulatory T cell (Treg) afferent lymphatic migration is important for islet allograft survival. Treg express high levels of lymphotoxin (LT) and bind the LT…2019 American Transplant Congress
Reduction of Pre-Existing Alloantibodies in Highly Sensitized Belatacept-Treated Kidney Recipients
*Purpose: Recent evidence suggests that belatacept reduces the durability of pre-existing antibodies to class I and class II human leukocyte antigens (HLA). Belatacept has a…2018 American Transplant Congress
Ex Vivo Expanded Regulatory T Cells Combined with Short-Term Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…2018 American Transplant Congress
Belatacept-Refractory CD8+CD28–CD38hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L
Calcineurin inhibitors (CNIs) and corticosteroids (CSS) have substantial untoward side effects, most notably nephrotoxicity. Consequently, the FDA approved belatacept for maintenance immunosuppression. We recently completed…2018 American Transplant Congress
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression
Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 30
- Next Page »